Q2 reported revenue of $153.2 million increased 4% Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share Non-GAAP earnings* of $0.22...
Barchart Research What to Expect from BVS Earnings BVS Generated August 4, 2026 Current Price $13.42 EPS Estimate $$0.22 Consensus Rating Strong Buy Average Move 15.51% Bioventus May Be Approaching the...
DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will...
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President...
Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share Non-GAAP...
Barchart Research What to Expect from BVS Earnings BVS Generated May 5, 2026 Current Price $10.68 EPS Estimate $$0.09 Consensus Rating Strong Buy Average Move 18.73% Bioventus Reports Tomorrow With Peripheral...
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today...